Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and ... ( SAN DIEGO July 30 /- Anadys Pharm...)

Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights

Date:7/30/2008

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the second quarter ended June 30, 2008.

"The first half of 2008 has been a remarkably productive time at Anadys," said Steve Worland, Ph.D., President and CEO. "Through the focused efforts of our employees, we have initiated dosing in three clinical programs in six months. For hepatitis C, we commenced dosing in our Phase I clinical trial of ANA598 during the second quarter, and are happy to announce today that we have now commenced dosing in our Phase I clinical trial of ANA773 for HCV. We also continue to enroll patients in our ongoing clinical trial of ANA773 for oncology. We are proud of our progress to date and look forward to achieving additional clinical milestones in the coming months."

Financial Results

As of June 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $42.1 million.

During the second quarter of 2008 the Company had no revenue, compared to $1.3 million for the same quarter of 2007. The revenue in the second quarter of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $5.5 million for the second quarter of 2008, compared to $7.0 million for the second quarter of 2007. The $1.5 million decrease primarily resulted from cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs. The
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:3/17/2010)... program that will allow customers to design their own unique shelter ... ... -- DHS Technologies recently launched a newly revised software program that ... , , , ,VTAP 2.0, or the second edition of the ... 3-D renderings of Deployable Rapid Assembly Shelter ( DRASH ) system ...

(Date:3/16/2010)... 16, 2010)The first known patient cases using magnetic ... (cryoablation) to treat prostate cancer recurrence after surgical ... physicians at the Society of Interventional Radiology,s 35th ... patients have also failed salvage radiation treatment and ... focal therapy offers a new treatment choice for ...

(Date:3/16/2010)... (March 16, 2010)Pancreatic cancerknown as the most fatal ... new therapy. A promising approach may come in ... therapeutic agent to kill cancerin a novel procedure ... Interventional Radiology,s 35th Annual Scientific Meeting in Tampa, ... offer minimal benefit, entirely new approaches are needed. ...

(Date:3/16/2010)... , ... , ... ... EDMONTON , March 16 /PRNewswire-FirstCall/ - BioMS ... ...

[0] DHS Technologies Launches VTAP 2.0 [0] The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer [0] Going for gold with a novel interventional radiology treatment for pancreatic cancer [0] BioMS Medical Announces 2009 Year End Results

... CINCINNATI, Aug. 31 Kendle (Nasdaq: KNDL ... that Senior Vice President and Chief Financial Officer ... Weisel Partners,Healthcare Conference 2007 at the Four Seasons ... scheduled for Wednesday, Sept. 5 at,2:40 p.m. Eastern ...

... 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... NewsMakers in the Biotech Industry conference in New,York. ... Thursday, September,6, 2007 at 2:00 p.m. Eastern Time ... . The presentation will be archived for seven ...

... (Nasdaq and SWX: BMRN) announced today that,Jean-Jacques Bienaime, ... update at the BioCentury NewsMakers in the Biotech ... 6, 2007 at 10:30 a.m.,ET. Interested parties ... presentation,via the investor section of the BioMarin website, ...

Other Biology Technology:Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007 2 BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2 BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3

Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007 BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference BioMarin to Present at the BioCentury NewsMakers Conference

(Date:3/16/2010)... of biofuels into agricultural systems presents new opportunities ... critical ecosystem services. Integrating perennial crops can help ... require an understanding of biomass productivity on specific ... farmers will need to know where their crops ... processes, such as hill slope length and gradient, ...

(Date:3/16/2010)... at the California Institute of Technology (Caltech) and the ... injecting a simple hormone into leeches creates a novel ... work together to produce species-specific reproductive behavior. , A ... online edition of the journal Current Biology . ... Circuitry at Caltech and first author of the paper, ...

(Date:3/16/2010)... years of satellite data have found that the amount ... markedly over the last three decades. Most of the ... been little or no increase in tropical regions. ... one line of latitude 32.5 degrees a ... hemisphere and the country of Uruguay in the southern ...

Breaking Biology News(10 mins):The effect of landscape position on biomass crop yield 2 Caltech and UCSD scientists establish leech as model for study of reproductive behavior 2 Caltech and UCSD scientists establish leech as model for study of reproductive behavior 3 UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 2 UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 3 UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 4 Impliant Granted Two New U S Patents and Successfully Defends European Patent Opposition Case 48321 1 Impliant Granted Two New U S Patents and Successfully Defends European Patent Opposition Case 48321 2 HealthCore Invites Community based Practitioners to Participate in Real world Research Network 48319 1 HealthCore Invites Community based Practitioners to Participate in Real world Research Network 48319 2 HealthCore Invites Community based Practitioners to Participate in Real world Research Network 48319 3 HealthCore Invites Community based Practitioners to Participate in Real world Research Network 48319 4 White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 1 White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 2 White Paper Explains Package Validation Requirements For Medical Devices 26 Combinatory Products 48317 3

[0] The effect of landscape position on biomass crop yield [0] Caltech and UCSD scientists establish leech as model for study of reproductive behavior [0] UV exposure has increased over the last 30 years, but stabilized since the mid-1990s

... In the March 3 issue of Nature, Johns Hopkins ... different activities actually come together to turn the liver ... the liver's production of sugar is a damaging problem ... a target for future drugs to fight the disease, ...

... Johns Hopkins researchers report that two proteins best known ... the liver into a sugar-producing factory when food is ... damaging problem in people with diabetes, the proteins' interaction ... the disease, the researchers say. , Under normal circumstances, ...

... A team of scientists from Colombia, the United States ... the genetic problems behind the very rare Roberts syndrome, ... and shortened limbs that resemble those of babies whose ... is reported in the April 10 advance online section ...

Other Biology News:Computational verification of protein-protein interactions by orthologous co-expression 2 Computational verification of protein-protein interactions by orthologous co-expression 3 PHACCS, an online tool for estimating the structure and diversity of uncultured viral communities using metagenomic information 2 PHACCS, an online tool for estimating the structure and diversity of uncultured viral communities using metagenomic information 3 15-year hunt finds cause of pseudothalidomide syndrome 2 15-year hunt finds cause of pseudothalidomide syndrome 3 15-year hunt finds cause of pseudothalidomide syndrome 4

Computational verification of protein-protein interactions by orthologous co-expression PHACCS, an online tool for estimating the structure and diversity of uncultured viral communities using metagenomic information 15-year hunt finds cause of pseudothalidomide syndrome

... chromatography system, uses the highly sensitive and ... is provided by the CE 4900 interface and ... CE 4100 dual piston pump. A ... system can be upgraded to provide binary or ...

Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...

... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: barcoded ...

... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...

Biology Products:

Adept HPLC System 9, Isocratic Refractive Index from Cecil Instruments Ltd.Mouse Anti-Human QPCT Monoclonal Antibody, Unconjugated, Clone 4E11 from Novus Biologicals Corning ultragaps Coated Slides,Bar-Coded from Sigma-Aldrich Freedom EVO384R from Tecan

Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and ...( SAN DIEGO July 30 /- Anadys Pharm...)